Ann: June 2021 Quarterly Activities and Cashflow Reports, page-3

I think this is a very promising update. ( I do understand the frustration of Auscann LTH, a drop from 1.5 dollars to 10 cents is not something easy to digest)
They have reduced cash burn and the company is funded enough for the next 6 to 8 quarters.
Meeting with FDA CVM is within this quarter and this will then lead to the Phase 2 for CPAT-01,the most promising candidate.
Dermancann registration application in South Africa has already been done and we can expect an outcome sometime next year.
Cannapal has given an new lease of life to Auscann and CPAT-01 and Dermacann can take this company to at least 500million market cap by the end of next year.